This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis of the clinical study was based on modified intention to treat in which missing cases were excluded. The primary outcome measure was the recurrence of a BCC for both samples of patients. The secondary outcome measures were frequency of complications, quality of life and anxiety. Quality of life and anxiety were estimated using two tools, the Dutch version of the Nottingham Health Profile (NHP) and a domain-specific questionnaire (the Dutch version of the State-Trait Anxiety Inventory, STAI). Both instruments were administered at baseline and after 6 months. The authors did not state whether the study groups had comparable clinical and demographic factors at baseline, but the groups were likely to have been similar given the randomisation process.
Effectiveness results
In the primary BCC sample, there were 5 recurrences in the SE group and 3 in the MMS group at 30 months' follow-up.
In the recurrent BCC sample, there were 3 recurrences in the SE group and 0 in the MMS group at 18 months' followup.
In the primary BCC sample, there were 28 (14%) complications in the SE group and 24 (12%) in the MMS group.
In the recurrent BCC sample, there were 19 (19%) recurrences in the SE group and 8 (8%) in the MMS group, (p=0.02).
Mean scores for anxiety and quality of life were not statistically different between the groups.
Clinical conclusions
The effectiveness analysis showed that fewer recurrences and fewer complications were observed among patients undergoing MMS in comparison with those undergoing SE.
Measure of benefits used in the economic analysis
The summary benefit measure was the difference in recurrence rate between the groups. This was derived directly from the effectiveness analysis. An annual discount rate of 4% was applied.
Direct costs
The analysis of the costs was conducted from the viewpoint of the hospital. The categories of costs included were personnel and material costs of all diagnostic procedures, surgery, outpatient visits and overheads. Some unit costs were presented separately from the quantities of resources used. Resource use was based on actual resource consumption in the sample of patients included in the clinical trial, using a micro-costing approach. The costs were estimated from the authors' institution and from Dutch guidelines. Discounting was relevant, as the costs were incurred during 30 months, and an annual rate of 4% was applied to costs incurred after the second year. The price year was 2001.
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Statistical analysis of costs
The costs were analysed by the intention to treat principle with mean substitution of missing values. Regression analysis was performed to investigate the effect of location and histopathologic sub-type on the cost-difference between the groups. If non-normal distributions were present, log-transformation of the costs was applied. The bootstrap method was used to determine confidence intervals (CIs).
Indirect Costs
The indirect costs were not included in the economic analysis.
Currency
Euros (EUR). The exchange rate from euros to US dollars ($) and UK pounds sterling () in 2001 was EUR 1 = $0.89 = 0.69.
Sensitivity analysis
Univariate sensitivity analyses were carried out to assess the robustness of cost-effectiveness ratios to variations in personnel costs, effect difference between groups, and actual recurrence rates. Alternative published values, as well as authors' opinions, were used. Bootstrapping with 1,000 replications was performed to define CIs around the costeffectiveness ratios. Subsequently, acceptability curves were generated for different threshold values.
Estimated benefits used in the economic analysis
In the sample of primary BCC, the expected rate of recurrence avoided was 0.9812 with MMS and 0.9725 with SE (difference 0.0091).
In the sample of recurrent BCC, the expected rate of recurrence avoided was 1.000 with MMS and 0.968 with SE (difference 0.032).
Cost results
In the sample of primary BCC, the expected costs were EUR 1,132 with MMS and EUR 866 with SE (difference EUR 266).
In the sample of recurrent BCC, the expected costs were EUR 1,159 with MMS and EUR 900 with SE (difference EUR 259).
Different in costs reached statistical significance in both the primary and recurrence BCC groups.
The higher costs associated with MMS were mainly due to the personnel costs arising from longer theatre time.
The regression analysis showed that location and histopathologic sub-type had no effect on the cost-difference between the groups.
Synthesis of costs and benefits
Incremental cost-effectiveness ratios (ICERs) were calculated in order to combine the costs and benefits of the alternative treatments.
The incremental cost per recurrence avoided with MMS over SE was EUR 29,231 in the sample of primary BCC and EUR 8,094 in the sample of recurrent BCC.
The most interesting results of the univariate sensitivity analysis were that substantial reductions in the ICER could be achieved when a larger difference in treatment effectiveness between groups was considered. Also, a longer follow-up period (5 years) substantially reduced the ICER (e.g. this was EUR 4,047 for the recurrence BCC group).
